Endoskopische Optionen zur Gewichtsreduktion bei Adipositas

Zusammenfassung

Endoskopische Verfahren haben das Potenzial, die therapeutische Lücke zwischen medikamentöser und operativer Therapie der Adipositas zu schließen.

Dabei haben endoluminale Verfahren ein deutlich höheres Wirkungspotenzial als der medikamentöse Therapieansatz und dazu ein geringeres Risikoprofil als die Chirurgie. Es gibt eine Vielzahl von verschiedenen primären endoskopischen Therapien, es stehen Bridging-Therapien zur Verfügung, und auch im Rahmen des Behandlungsalgorithmus von chirurgischen Komplikationen hat die Endoskopie einen herausragenden Stellenwert.

Aus diesem Grund hat sich mittlerweile ein eigenständiges Fachgebiet in der Endoskopie entwickelt: Die bariatrische Endoskopie. Die bariatrische Endoskopie setzt exakte chirurgische und anatomische Kenntnis der adipositaschirurgischen Verfahren als auch das Verständnis für die resultierenden pathophysiologischen Veränderungen voraus.

Summary

Endoscopic bariatric procedures are indicated in obesity class I and II. Endoluminal procedures have a higher therapeutical impact than weight reduction drugs, while their risk is lower than that of surgical procedures. Endoscopical treatment comprise primary procedures for weight loss as well as bridging procedures, which are indicated for conditioning therapy prior to surgery. In the context of treatment algorithm of post-surgery complications, endoscopy is most significant. That`s why, bariatric endoscopy has been established as particular sub-specification. Knowledge of bariatric surgery procedures as well as of postoperative resulting pathopysiology is requested in bariatric endocopy.

Schlüsselwörter

Endoskopische Verfahren - Gewichtsreduktion - Adipositas

Keywords

Bariatric endoscopy - weight reduction - obesity

• Literatur

• 1 World Health Organisation. Obesity and Overweight: Fact sheet No. 311. January 2015 http://www.int/mediacentre/factsheets/fs311/en/ [Accessed 20. September 2016].
• 2 Koppelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643.
• 3 Indisziplinäre Leitlinie der Qualität S3 zur “Prävention und Therapie der Adipositas”. Version 2.0; April 2014
• 4 Mingrone G. et al. Bariatric-Metabolic Surgery vs. Conventional Medical Treatment in obese patients with type 2 diabetes: 5 Year follow-up of an openlabel, single-centre, randomised controlled trial. Lancet 2015; 386: 964-973.
• 5 Chiang AL, Ryou M. Endoscopic treatment of Obesity. Curr Opin Gastroenterol 2015; 31: 352-358.
• 6 Kumar N. Weight loss endoscopy: Development, applications, and status. World J Gastroenterol 2016; 22 (31) 7069-7079.
• 7 Sullivan S, Kumar N, Edmundowicz SA. et al. ASGE position statement on endoscopic bariatric therapies in clinical practice. Gastrointest Endosc 2015; 82: 767-772.
• 8 Abu BKDayyeh, Edmundowicz SA, Jonnalagadda S. et al. Endoscopic bariatric therapies. Gastrointest Endosc 2015; 81: 1073-1086.
• 9 Abu BKDayyeh, Kumar N, Edmundowicz SA. et al. ASGE bariatric endoscopy task force systemic review and meta-analysis assing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015; 82: 435-438.
• 10 Tsigos C, Hainer V, Basdevant A. et al. Criteria for EASO-collaborating centres for obesity management. Obes Facts 2011; 04: 329-333.
• 11 Paricha PJ. Hunger games: is your stomach making you fat?. Gastroenterology. 2015; 148: 491-493.
• 12 Meyer-Gerspach AC, Wölnerhannsen B, Beglinger B. et al. Gastric and intestinal satiation in obese and normal weight healthy people. Physiol Behav. 2014; 22; 129: 265-271.
• 13 Ponce J, Woodman G, Swain J. et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis 2015; 11: 874-881.
• 14 Yorke E, Switzer NJ, Reso A. et al. Intragastric balloon for the management of severe obesity: A systematic review. Obes Surg 2016; 26: 2248-2254.
• 15 Sullivan S, Stein R, Jonnalagadda S. et al. Aspiration therapy leads to weight loss in obese subjects: A pilot study. Gastroenterology 2013; 145 (06) 1245-1252.
• 16 Thompson CC, Abu BKDayyeh, Kushner R. et al. The AspireAssist is an effective tool in the treatment of class II and class III obesity: results of a one-year clinical trial. Gastroenterology 2016; 150: S86.
• 17 Lopez-Nava G, Baitista-Castano I, Jimenez A. at al. The primary obesity surgery endoluminal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis 2015; 11: 861-865.
• 18 Aharaiha RZ, Kedia P, Kumpta N. et al. Initial experience with endoscopic sleeve gastroplasty: technica success and reproducibility in the bariatric population. Endoscopy 2015; 47: 164-166.
• 19 Lopez-Nava G, Galvao MP, de Bautista-Castano I. et al. Endoscopic sleeve gastroplasty for the treatment of obesity. Endoscopy 2015; 47: 449-452.
• 20 Lopez-Nava G, Shaharia RZ, Galvao MP. et al. Endoscopic sleeve gastroplasty for obesity: a multi-center study of 242 patients with 18 months follow-up. Gastroenterology 2016; 150: S26.
• 21 Abu BKDayyeh, Acosta AJCardenas, Camilleri M. et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol. 2015 31. S1542–3565(15)01714–0.
• 22 De Moura EG, Martins BC, Lopes GS. et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endocoppically deployed duodeno-jejunal bypass-liner. Diabet Technol Ther 2012; 14: 183-189.
• 23 Escalona A, Pimental F, Sharp A. et al. Weight oss and metabolic improvement in morbidely obese subjects implanted for 1 year with an endocoppically deployed duodeno-jejunal bypass-liner. Ann Surg 2012; 255: 1080-1085.
• 24 Koehestanie P, de Jonge C, Berends FJ. et al. The effect of the endoscoic duodenal bypass on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg 2014; 260: 984-92.
• 25 Shouten R, Rijs CS, Bouvy ND. et a. A multicenter, randomized efficacy study of the EndoBarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg 2010; 251: 236-243.
• 26 Rodriguez L, Reyes E, Fagalde P. et al. Pilot clinical study of an endoscopic removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther 2009; 11: 725-732.
• 27 Kumbhan V, Oberbach A, Nimgeonkar A. Primary therapies for obesity and metabolic diseases. Curr Opin Gastroenterol 2015; 31: 351-358.
• 28 Cohen RV, Neto MG, Correa A. et al. A pilot study of the duodenal jejunal bypass liner in low body mass index type 2 diabetes. J Clin Endocrinol Metab 2013; 98: E279-282.
• 29 ENDO trial placed on enrolment hold. March 2015 http://www.gidynamics.com/media-press-release.php.?d=139 [Accessed on 23. September 2016].